Overview of Patient-Reported Outcomes in Haemophilia Gene Therapy
Transfusion Medicine and Hemotherapy · 21.05.2026 · 1-7
DOI: 10.1159/000552536 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transfusion Medicine and Hemotherapy, online erschienen am 21.05.2026. Verfasst von Wolfgang Miesbach. Beteiligte Einrichtung: Medical Clinic 2, University Hospital Frankfurt, Frankfurt, Germany. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background: Three adeno-associated virus-based gene therapies for haemophilia have received regulatory approval in Western countries since 2022, yet commercial uptake has been slow. Traditional clinical endpoints – annualised bleeding rate and factor activity levels – document haemostatic efficacy, but fail to capture what matters most to patients. Both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) increasingly recognise patient-reported outcomes (PROs) as meaningful endpoints for regulatory and health technology assessment decisions. Summary: Narrative review of peer-reviewed literature in PubMed and Web of Science (2017–2026) covering PRO instruments, clinical trial evidence, cost-effectiveness analyses, and qualitative patient data in haemophilia gene therapy. Six trials have reported PRO data using a total of 12 different instruments, of which five principal measures of which five measures are central to the quality-of-life evidence: the disease-specific Haem-A-QoL and Haemo-QoL-A, the generic EQ-5D-5L, and the gene therapy-specific coreHEM Mental Health Outlook (coreHEM-MHO). Across all studies, gene therapy produced clinically meaningful improvements in quality of life. Total disease-specific quality-of-life scores improved by 6–15 points across trials – exceeding established clinically important difference thresholds – with the largest gains in the Treatment and Dealing with Haemophilia domains. EQ-5D-5L utility indices increased significantly in multiple trials. In the SPK-9001 long-term follow-up, durable Haem-A-QoL gains were confirmed through 156 weeks. The coreHEM-MHO, developed to capture psychological dimensions unique to gene therapy such as durability anxiety and disease identity adjustment, has been piloted in BENEGENE-2. Qualitative interviews documented profound reductions in treatment burden and improved daily functioning. Key Messages: PRO evidence consistently demonstrates that haemophilia gene therapy delivers quality-of-life benefits that extend well beyond what traditional clinical endpoints capture. These PRO-derived improvements are also the principal driver of gene therapy’s economic value since cost-effectiveness models show substantial gains in health-related quality of life but negligible gains in life expectancy. Priorities include standardised coreHEM measurement, long-term registries, and ensuring certified haemophilia centres are equipped for systematic PRO follow-up.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Clinic 2, University Hospital Frankfurt, Frankfurt, Germany.
Zitieren
APA
Miesbach, W. (2026). Overview of Patient-Reported Outcomes in Haemophilia Gene Therapy. Transfusion Medicine and Hemotherapy, 1-7. https://doi.org/10.1159/000552536
Vancouver
Miesbach W. Overview of Patient-Reported Outcomes in Haemophilia Gene Therapy. Transfusion Medicine and Hemotherapy. 2026:1-7. doi:10.1159/000552536
BibTeX
@article{Miesbach2026,
author = {Miesbach, Wolfgang},
title = {Overview of Patient-Reported Outcomes in Haemophilia Gene Therapy},
journal = {Transfusion Medicine and Hemotherapy},
year = {2026},
pages = {1--7},
doi = {10.1159/000552536}
}
EUVIMED